[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367281-105":59,"doc-detail-367281-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","pan-cancer-analysis-of-pdgfrb-laying-the-foundation-for-the-development-of-targeted-immunotherapy-drugs","Pan-cancer analysis of PDGFRB - Laying the foundation for the development of targeted immunotherapy drugs","","PDGFRB is a tyrosine-protein kinase abnormally expressed across many cancers and has been linked to cancer prognosis, but a comprehensive pan-cancer analysis was lacking. Using TCGA and GTEx, PDGFRB expression patterns were evaluated across tumor and clinical stage samples, supported by differential expression statistics in R. Validation used immunohistochemical staining in cholangiocarcinoma and esophageal cancer, with additional TARGET follow-up data. Kaplan–Meier and univariate Cox analyses assessed survival associations, while immune infiltration, immune pathway gene correlations, and tumor stemness scores connected PDGFRB to immune regulation, checkpoints, and poor outcomes. The study supports PDGFRB as a prognosis- and immunity-related candidate biomarker and potential immune checkpoint.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pan-cancer-analysis-of-pdgfrb-laying-the-foundation-for-the-development-of-targeted-immunotherapy-drugs/367281/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-of-pdgfrb-laying-the-foundation-for-the-development-of-targeted-immunotherapy-drugs/367281.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is PDGFRB and why was it investigated?","Question",{"text":113,"@type":114},"PDGFRB is a type III tyrosine-protein kinase abnormally expressed in multiple cancers and associated with prognosis, making it a potential biomarker. The study investigates whether PDGFRB shows consistent patterns across cancers and relates to immune regulation.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were PDGFRB expression and differential patterns analyzed?",{"text":118,"@type":114},"TCGA and GTEx databases were used to quantify PDGFRB expression. Differential expression across normal, tumor, and different clinical stage samples was calculated with R software.",{"name":120,"@type":111,"acceptedAnswer":121},"How did the study link PDGFRB to immunity and patient outcomes?",{"text":122,"@type":114},"Survival associations were tested using Kaplan–Meier and univariate Cox regression analyses. Immune infiltration was analyzed, and correlations between PDGFRB and immune pathway marker genes were evaluated, connecting PDGFRB expression to immune checkpoints, immune activation/suppression, and poor survival.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},367281,1790332062,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","®  \n Observational Study   \nPan-cancer analysis of PDGFRB  \nLaying the foundation for the development of targeted immunotherapy drugs  \nQian Gao, MMa , Yan Cui, MMb , Feng Gao, MDc , Yan Yang, MDc , Weizhong Huangfu, MDd , Minjie Wang, MDa ,*  \n\n| Abstract\u003Cbr>PDGFRB is a type III tyrosine-protein kinase that is abnormally expressed in various cancers and can serve as a biomarker for cancer prognosis, as studies have demonstrated. However, a pan-cancer analysis of PDGFRB has not yet been carried out. The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases were utilized to analyze PDGFRB expression levels. Differential expression of PDGFRB in standard, tumor, and different clinical stage samples was calculated using R software (version 3.6.4) . Immunohistochemical staining for Cholangiocarcinoma (CHOL) and Esophageal carcinoma (ESCA) was conducted on clinical patient samples. High-quality prognostic datasets from TCGA have been published in previous studies. Additionally, the TARGET follow-up data were obtained as supplementary information, excluding models with a follow-up period of less than 30 days. After conducting a rain analysis of PDGFRB, Kaplan–Meier and univariate Cox regression analyses were performed using the R software package. The DNA tumor stemness scores, derived from methylation signatures for each tumor, were obtained from previous studies. Finally, the infiltration of immune cells was analyzed, and the Pearson correlation between PDGFRB and five immune pathway marker genes was assessed. PDGFRB exhibited differential expression across most tumor types in TCGA, indicating a correlation with poor survival outcomes. The expression of PDGFRB influences the regulation of the immune system and is closely associated with immune cell infiltration, immune checkpoints, immune-activating genes, immune suppressor genes, chemokines, and chemokine receptors. PDGFRB is a cancer gene closely associated with prognosis and immunity in cancer patients, and it may serve as an immune checkpoint. |\n| --- |\n| Abbreviations: ALL = acute lymphoblastic leukemia, ACC = adrenocortical carcinoma, BLCA = bladder urothelial carcinoma, BRCA = breast invasive carcinoma, CESC = cervical squamous cell carcinoma and endocervical adenocarcinoma, CHOL = cholangiocarcinoma, COAD = colon adenocarcinoma, COADREAD = colon adenocarcinoma/rectum adenocarcinoma esophageal carcinoma, ESCA = esophageal carcinoma, GBM = glioblastoma multiforme, GBMLGG = glioma, HNSC = head and necksquamous cell carcinoma, KICH = kidney chromophobe, KIPAN = pan-kidney cohort (KICH+KIRC+KIRP), KIRC = kidney renal clear cell carcinoma, KIRP = kidney renal papillary cell carcinoma, LAML = acute myeloid leukemia, LGG = brain lower grade glioma, LIHC = liver hepatocellular carcinoma, LUAD = lung adenocarcinoma, LUSC = lung squamous cell carcinoma, MESO = mesothelioma, OV = ovarian serous cystadenocarcinoma, PAAD = pancreatic adenocarcinoma, PCPG = pheochromocytoma and paraganglioma, PRAD = prostate adenocarcinoma, READ = rectum adenocarcinoma, SARC = sarcoma, SKCM = skin cutaneous melanoma, STAD = stomach adenocarcinoma, STES = stomach and esophageal carcinoma, TGCT = testicular germ cell tumors, THCA = thyroid carcinoma, THYM = thymoma, UCEC = uterine corpus endometrial carcinoma, UCS = uterine carcinosarcoma, UVM = uveal melanoma. |\n| Keywords: cancer, immune checkpoint, PDGFRB, TCGA |\n\nQG and YC contributed equally to this work.  \nThis research was funded by “Grassland talent project youth innovation and entrepreneurship level one project, grant numbers DC2300001103” and “The Inner Mongolia Autonomous Region has launched innovative support programs for returnees, grant numbers DC2200003492” and “Key Laboratory of Quality Research and Efficacy Evaluation of Traditional Chinese Medicine (Mongolian medicine), Inner Mongolia Medical University, grant Numbers PTKY2023023”. The authors have no conflicts of interest to disclose.  \nThe datasets generated during a","cbCaif46nIL6yrFv","https://ap.wps.com/l/cbCaif46nIL6yrFv","pdf",4821150,11,"English","# Introduction\n## Observational study background and research rationale\n## Pan-cancer expression analysis using TCGA and GTEx\n## Survival association and clinical validation\n## Immune infiltration, pathway correlations, and stemness links","[{\"question\":\"What is PDGFRB and why was it investigated?\",\"answer\":\"PDGFRB is a type III tyrosine-protein kinase abnormally expressed in multiple cancers and associated with prognosis, making it a potential biomarker. The study investigates whether PDGFRB shows consistent patterns across cancers and relates to immune regulation.\"},{\"question\":\"How were PDGFRB expression and differential patterns analyzed?\",\"answer\":\"TCGA and GTEx databases were used to quantify PDGFRB expression. Differential expression across normal, tumor, and different clinical stage samples was calculated with R software.\"},{\"question\":\"How did the study link PDGFRB to immunity and patient outcomes?\",\"answer\":\"Survival associations were tested using Kaplan–Meier and univariate Cox regression analyses. Immune infiltration was analyzed, and correlations between PDGFRB and immune pathway marker genes were evaluated, connecting PDGFRB expression to immune checkpoints, immune activation/suppression, and poor survival.\"}]","Pan-cancer analysis of PDGFRB - Laying the foundation for the development of targeted immunotherapy drugs | PDF",1790170059,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b988a06b16786ccc9f4a70cf49fe90d1.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13aac72377826f48d481663d19117117.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11c2e263d2458f7196278afcd67de38a.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e141516b7c5859dfb8b84c7f5e86195.webp",980,1306]